Dosage of venetoclax/venetoclax in the treatment of myeloma

Venetoclax/Venetoclax is a small molecule BCL-2 inhibitor that kills tumors by restoring the apoptosis mechanism of tumor cells. Myeloma is a malignant neoplastic disease caused by excessive secretion of monoclonal immunoglobulin light chains, which can lead to bone damage and renal impairment. However, the situation is not set in stone as to whether venetoclax can directly treat myeloma and will need to be judged on a patient-by-patient basis. Clinical guidelines for venetoclax are not currently indicated for the treatment of myeloma.

Although venetoclax is mainly used clinically to treat certain hematological malignancies, such as chronic lymphocytic leukemia, acute myeloid leukemia, etc., it works by binding to a protein calledB-cell lymphoma 2 (Bcl-2), blocking its action and causing cancer cells to starve and die. However, it has no direct killing effect on myeloma itself.

Regarding the dosage of venetoclax, according to clinical guidelines:For patients withCLL/SLL, the starting dose of venetoclax is 20m daily g and gradually increase to 400 mg daily over five weeks (20 mg on the first week, 50 mg on the second week, 100 mg on the third week, and 200 mg daily in the fourth week), then continue at 400 mg daily. For AML patients, the starting dose is 100 mg and is increased to 400 mg per day over three days (100 mg on day 1, 200 mg on day 2, and 400 mg on day 3).

However, please note that this is just a general medication regimen, and the actual dosage may be adjusted based on the patient's specific condition and the doctor's recommendations. For the treatment of myeloma, venetoclax may not be the drug of choice. Patients should discuss the risks and benefits, as well as possible other treatment options, with their doctor in detail before considering using venetoclax.